Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

Abstract

Background Whether long-term suppression of replication of hepatitis B virus (HBV) has any beneficial effect on regression of advanced liver fibrosis associated with chronic HBV infection remains unclear. We aimed to assess the effects on fibrosis and cirrhosis of at least 5 years' treatment with tenofovir disoproxil fumarate (DF) in chronic HBV infection.Methods After 48 weeks of randomised double-blind comparison (trials NCT00117676 and NCT00116805) of tenofovir DF with adefovir dipivoxil, participants (positive or negative for HBeAg) were eligible to enter a 7-year study of open-label tenofovir DF treatment, with a pre-specified repeat liver biopsy at week 240. We assessed histological improvement (≥2 point reduction in Knodell necroinflammatory score with no worsening of fibrosis) and regression of fibrosis (≥1 unit decrease by Ishak scoring system).Findings Of 641 patients who received randomised treatment, 585 (91%) entered the open-label phase, and 489 (76%) completed 240 weeks. 348 patients (54%) had biopsy results at both baseline and week 240. 304 (87%) of the 348 had histological improvement, and 176 (51%) had regression of fibrosis at week 240 (p<0·0001). Of the 96 (28%) patients with cirrhosis (Ishak score 5 or 6) at baseline, 71 (74%) no longer had cirrhosis (≥1 unit decrease in score), whereas three of 252 patients without cirrhosis at baseline progressed to cirrhosis at year 5 (p<0·0001). Virological breakthrough occurred infrequently and was not due to resistance to tenofovir DF. The safety profile was favourable: 91 (16%) patients had adverse events but only nine patients had serious events related to the study drug.Interpretation In patients with chronic HBV infection, up to 5 years of treatment with tenofovir DF was safe and effective. Long-term suppression of HBV can lead to regression of fibrosis and cirrhosis.Funding Gilead Sciences.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)61425-1

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

See all 1,788

Metadata

Authors
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., Bornstein, J. D., Kitrinos, K. M., Subramanian, G. M., McHutchison, J. G., & Heathcote, E. J.
Affiliations
  • Inserm (FR)
  • Auckland City Hospital (NZ)
  • Beth Israel Deaconess Medical Center (US)
  • Monash Medical Centre (AU)
  • Weill Cornell Medicine (US)
  • Vanderbilt University (US)
  • Aristotle University of Thessaloniki (GR)
  • Gilead Sciences (United States) (US)
  • University of Toronto (CA)
Corresponding author
Marcellin, Patrick
Venue
The Lancet
Publisher
Elsevier BV
Published
2013-02
Volume
381
Issue
9865
Pages
468-475
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2090738619
Cited by
1,788
References
38
Citations by year
2026: 54 · 2025: 99 · 2024: 120 · 2023: 123 · 2022: 137 · 2021: 148 · 2020: 151 · 2019: 136 · 2018: 131 · 2017: 163 · 2016: 142 · 2015: 170 · 2014: 137 · 2013: 71
FWCI
90.42
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Gilead Sciences
  • Genentech
Topics
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords
tenofovir disoproxil fumarate, chronic hepatitis B, cirrhosis regression, liver fibrosis, antiviral therapy, HBV replication inhibition, long-term treatment safety, histological improvement, virological breakthrough, adefovir dipivoxil, liver biopsy, Knodell score, Ishak score, HBeAg status, drug resistance, adverse events
MeSH terms
Tenofovir, Adenine, Adult, Biopsy, Needle, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hepatitis B virus, Humans, Immunohistochemistry, Male, Middle Aged, Severity of Illness Index, Time Factors, Treatment Outcome, Safety Management, Reverse Transcriptase Inhibitors, Hepatitis B, Chronic, Organophosphonates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. https://app.cochat.ai/papers/10.1016/s0140-6736(12)61425-1
The paper
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., Bornstein, J. D., Kitrinos, K. M., Subramanian, G. M., McHutchison, J. G., & Heathcote, E. J. (2013). Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. The Lancet. https://doi.org/10.1016/s0140-6736(12)61425-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.